The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Expands manufacturing push & locks in major growth deals
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Subscribe To Our Newsletter & Stay Updated
